<SEC-DOCUMENT>0001144204-15-039548.txt : 20150629
<SEC-HEADER>0001144204-15-039548.hdr.sgml : 20150629
<ACCEPTANCE-DATETIME>20150629091038
ACCESSION NUMBER:		0001144204-15-039548
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150629
FILED AS OF DATE:		20150629
DATE AS OF CHANGE:		20150629

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO BLAST PHARMA LTD.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		15956729

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v414307_6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of: June 2015 (Report No.
4)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>BIOBLAST PHARMA LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant's name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">37 Dereh Menechem Begin St., 15<SUP>th</SUP>
Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Tel Aviv 6522042 Israel</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Form 20-F &nbsp;<FONT STYLE="font-family: Wingdings">&#120;
</FONT>Form 40-F <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Report of Foreign Private Issuer on
Form 6-K of the Registrant consists of the press release issued by the Registrant on June 29, 2015, announcing that it received
orphan drug designation from the European Commission for Cabaletta for the treatment of Spinocerebellar Ataxia (SCA), which is
attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The first paragraph of the press release
attached to this Form 6-K of the Registrant is incorporated by reference into the registration statement on Form S-8 (File No.
333-203114) of the Registrant, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this
report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit No.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release issued by BioBlast Pharma Ltd. on June 29, 2015, announcing that it received orphan drug designation from the European Commission for Cabaletta for the treatment of SCA.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="width: 7%; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>BioBlast Pharma Ltd. </U><BR>
        (Registrant)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
        By <U>/s/ Colin Foster</U></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Colin Foster</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer and President</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: June 29, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v414307_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BioBlast Pharma Receives Orphan Drug
Designation From The European<BR>
 Commission For Cabaletta For The Treatment Of Spinocerebellar Ataxia (SCA)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TEL AVIV, Israel, June 29, 2015</B> &ndash; BioBlast Pharma
Ltd. (NasdaqGM: ORPN), a clinical-stage orphan disease-focused biotechnology company, announced today that it has been granted
Orphan Drug Designation by the&nbsp;European Commission for Cabaletta for the treatment of Spinocerebellar Ataxia (SCA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BioBlast is currently conducting a Phase 2 study in patients
suffering from SCA3 in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cabaletta is a chemical chaperone that has been shown to prevent
pathological aggregation of proteins within cells in several diseases associated with abnormal cellular-protein aggregation, including
cell and animal models of Spinocerebellar Ataxia Type 3 (SCA3), Oculopharyngeal Muscular Dystrophy (OPMD), and other PolyA/PolyQ
diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BioBlast previously announced that it was starting a Cabaletta
Phase 3 study in OPMD in Canada and the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;With the grant announced today, we have now received
Orphan Drug Designation by both the European Commission and the U.S. FDA for Cabaletta in two diseases: Spinocerebellar Ataxia
Type 3 (SCA3) and Oculopharyngeal Muscular Dystrophy (OPMD). This is yet another important step in the development of this drug
candidate,&rdquo; stated Colin Foster, President and Chief Executive Officer of&nbsp;BioBlast.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>About Orphan Drug Designation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Orphan Drug Designation by the European Commission provides
regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening or chronically
debilitating condition affecting no more than five in 10,000 persons in the European Union (EU), and where no satisfactory treatment
is available. In addition to a 10-year period of marketing exclusivity in the EU after product approval, orphan drug designation
provides incentives for companies seeking protocol assistance from the EMA during the product development phase, and direct access
to the centralized authorization procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>About Spinocerebellar Ataxia Type 3 (SCA3; Machado-Joseph
Disease)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SCA3, also known as Machado Joseph disease, is the most common
disease among the cerebellar ataxias, which are a group of genetic diseases that are characterized by memory deficits, spasticity,
difficulty with speech and swallowing, weakness in arms and other muscular disorders. Symptoms can begin in early adolescence and
get worse over time. Eventually SCA3 leads to paralysis, and severe cases can lead to an early death in the fourth decade of life.
SCA3 is incurable, and there is currently no approved treatment for the disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>About BioBlast</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BioBlast Pharma is a clinical-stage biotechnology company committed
to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The company has a diverse
portfolio of product candidates with the potential to address unmet medical needs for incurable genetic orphan diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The BioBlast platforms are based on deep understanding of the
disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.
For more information please visit the Company's website, www.bioblast-pharma.com, the content of which is not incorporated herein
by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Forward-Looking Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">This press release contains
forward-looking statements within the meaning of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation
Reform Act of 1995 and other Federal securities laws. For example, we are using forward looking statements when we discuss </FONT>our
Phase 3 study in OPMD, <FONT STYLE="background-color: white">that our diverse portfolio of product candidates has the potential
to address unmet medical needs for incurable genetic orphan diseases, or that our platforms potentially address unmet medical
needs and offer solutions for several diseases that share the same biological pathology. In addition, historic results of scientific
research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not suggest
different conclusions or that historic results would not be interpreted differently in light of additional research and clinical
and preclinical trials results. Because such statements deal with future events and are based on BioBlast Pharma&rsquo;s current
expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of BioBlast
Pharma could differ materially from those described in or implied by the statements in this press release, including those discussed
under the heading &ldquo;Risk Factors&rdquo; in BioBlast Pharma&rsquo;s Annual Report on Form 20-F filed with the Securities and
Exchange Commission (&ldquo;SEC&rdquo;) on March 31, 2015, and in any subsequent filings with the SEC. Except as otherwise required
by law, BioBlast Pharma disclaims any intention or obligation to update or revise any forward-looking statements, which speak
only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONTACT:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. Investor Contact</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Andrew McDonald</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Founding Partner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Advisors, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Andrew@LifeSciAdvisors.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">646-597-6987</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``U`/@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BHKBXAM
M('GGD"1H,LQ[5P6H>,+S5+TV6EM]FAYW3XRVT=3[4FU%7>PTFW9'H)90<$@'
MZTI(`R>E>6M>R1292665N[S-N8GU]JFOO%=]8^&YTEDS+,"D+'[WN?H*\W#Y
MMA\15]E3NWWMH=M7+ZU*G[2=DO74S_&OC.>^OY-/T^8I:1DJS*?]8>_X5E>&
MM<NM%O$DB<F(G]Y'GAA6#!9W5Q)F.&1^_`JW$KQ/MD4JP[$8KTSA/?[:=+JV
MCGB.4D4,I]JEKGO!5PUQX:@W'/EL4'T%=#0`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!Y;XZ\1M=:@^GPOBW@.&Q
M_$W_`-:L#0+I/[0>)B`TT3(A_P!H]!6%>27"W<JW((F#'>#ZU6$CA@P)!!R"
M*BK352#@]FK%0FX24ET/6M%\/#4[669IO+=6VJ"NX`^XK0_X0.R>03W$S7%Q
MC&Z5<J!Z!>U87@3Q=`\[6=^PBFD`"R$X5S[^AKTKMFN+`X&&&H^SMKU:Z_,Z
ML5BI5JG-?3HNQPVMZ))IEFLJ7I=5.-A&"/I7-:D@O]/E>0#SK="ZR=]HZ@UM
M>(M1BN/%KV*R!A):C9SQO["J^F:)<ZJ'B52L+_)(Q[+WQ[]*\JK0G1S*G["_
M++?5M>?<]"%6-7!3]K:Z\K>AU/@>!H/"UL6',I,@^AKE/$/B#7KSQL^BZ)=+
M$``F"<`-W)->DQ11VMJD4:@1QIA0/05XQI>EWGBOQ=JMW:7AM"K,_FCW.,?I
M7TIX9T'A[Q1K]KXO70=7DCN-S;2R<[3ZY]*UUEU*Z^(16#6H39Q#Y[19.<#J
M-OK[URG@&1-/\7W]I=I'/<JDA^U9R5V]<'WJ#PO=R13>)/$0YE@A8H3_`'F/
M'\J`/4[_`,1Z/ID_DWNHP0RXSL9N:M)J%M<:>UY;SI+!L+!U.17E'A;P]8:Q
MH.IZ[K4IE?Y@&9L;2!G)_.H/"E[+:>"_$K>8PB6-1%D\;CD<?I0!8TS6/&7B
M'[;<6%_&D5L=S*S;>N3@>O2NB\'>,;S5-%U)]1"F2RCW>:HQN!!Z^_%<1IWA
MN_?P5=:S!J1@CRV^#)4.H]ZU=+U*&'X5:DL<"Q2EO)=Q_'NZ&F(V_AA=WU__
M`&C=WES+*@*JGF-D#J3_`$KK;GQ7H-G.T-QJMLDB]5+9Q7EQU"XT/X;6D%N3
M'-J4SL7'!V#C%0^(=`T[0_"-@[?O-4NR)&?=T7'0#TY%(9[$-7T\Z?\`;_MD
M/V3KYN[Y:K6OB;1;XR"VU*"0QH7?:>BCO7GOB#P[J,O@31!90M(EO$6GC3J2
M>=V._>I_"4WAW4-'U';IOV6ZCM2DX5OOIW(/;I0!KV'Q$@OO%4FGDPPV*;@L
M[-_K"#Q^==E>7'V>QFG!^XA8&O)OAOX9L-7DNKR\B9Q`Z^3\V.>3_A7I/B67
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MJB74&!(JC`8=FKQFX\Z>9YI6+.YRQ/<UT/@"ZEM?%MJJ9Q+F-A[&O?ITU"$8
MKHK'D3FYR<N[N>UW,;S6TL:/L=U*AO2O.H/AA>6ID^SZX\0DX?8I&[ZX->E4
M59!R.D>`K31=/O([>=I+VXC,9N77E0?04[P_X(@TC1[[3[F;[0EYQ(0,<8KK
M**`/,U^%][%YMI#K3II\K9=`#S]1G!K?O/`ULWA0:'8S&!3()'E(R7(ZYKK:
M*`/-D^%UR;=;677)?LH.?+53C\LXK9U'P'!-X;AT6QN#;PI)YCLPW%V]3784
M4`<=J_@.'4O#5AIBW!26R7;'*1P?7-8K_"R6X@A-QJ\DDZ?+\PRJKV`KTNB@
M#C=;\):M>7,<VGZU);*L*Q&-<J,`>Q[T[0_`5MI&F7UN]RTL]['LDEQC:/:N
MPHH`XGPCX(NO#6J27#:@98"I41`$!L]S72:QI;:I"D0E\L*<GC.:TJ*SK4H5
MH.G-73+IU)4Y*4=T0VL`MK6*!3D(H7-9VK:,=4GB<S[$C&-N*UZ*BKAJ=6G[
M*:]W33T'"M.$^>+U,?5=$.I2PGSMB1#&W%,U?0!J$L<\4OERH`OU`Z5MT5E4
MR_#U.;FC\5K_`"V-(8JK#EY7MM\SG(O"YCO(KEKIG=2&;<.IJVNB?\3LZB\V
M[G(3'2MBBIAEN&AI&/6^[W74<L96EN^EOD9.K:,=4FA8S;%C[8ZTW4M$.H74
M$IFVI$`-N.M;%%7/`T*CDY1^*S?RV)CB:L;6>U[?,Q[_`$0WVH0W#382,`;,
M>E1:IX?-[>K=P3>5)QG\.];M%34R_#U%)2C\3N]7NAPQ=6%K/96.?M?#(MM1
MBNA<ERAW'<.2:*Z"BM</A:6'3C25D]2*M:=5IS=[!111709#719$9'4,K#!!
M&0:XS6O`6ER++=VS-;D`L4494_3THHH`\\N;%([KR0Q(SC.*]'\'>$[+3E34
M][2W#KA=PP$'?%%%`'8T444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
8`!1110`4444`%%%%`!1110`4444`?__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
